Table 1.
Clinicopathological features among the four cohorts.
| TCGA_TCGA | GSE46602 | GSE70768 | MSKCC | Total | |
|---|---|---|---|---|---|
| (n = 431) | (n = 27) | (n = 108) | (n = 136) | (n = 702) | |
| Age (years) | |||||
| Mean (SD) | 60.9 (6.7) | 62.5 (6.1) | 60.4 (6.6) | 58 (6.7) | 60.4 (6.8) |
| Median (min, max) | 61 (41, 78) | 63 (46, 71) | 62 (41, 73) | 57.8 (37.3, 72.8) | 61 (37.3, 78) |
| PSA (ng/ml) | |||||
| Mean (SD) | 1 (4) | 19.8 (10) | 8.6 (3.7) | 12.2 (44.3) | 5.1 (20.6) |
| Stage | |||||
| Stage II | 164 (38.1%) | 13 (48.1%) | 33 (30.6%) | 85 (62.5%) | 295 (42.0%) |
| Stage III | 259 (60.1%) | 14 (51.9%) | 75 (69.4%) | 44 (32.4%) | 392 (55.8%) |
| Stage IV | 8 (1.9%) | 7 (5.1%) | 15 (2.1%) | ||
| Gleason | |||||
| 6 | 40 (9.3%) | 9 (33.3%) | 16 (14.8%) | 40 (29.4%) | 105 (15.0%) |
| 7 | 213 (49.4%) | 15 (55.6%) | 84 (77.8%) | 76 (55.9%) | 388 (55.3%) |
| 8 | 55 (12.8%) | 2 (7.4%) | 8 (7.4%) | 10 (7.4%) | 75 (10.7%) |
| 9 | 120 (27.8%) | 1 (3.7%) | 0 (0.0%) | 10 (7.4%) | 131 (18.7%) |
| 10 | 3 (0.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 3 (0.4%) |